BPC-157 — “Body Protection Compound” — is a synthetic 15-amino-acid peptide studied for cytoprotective and tissue-repair activity in preclinical research. Supplied as a lyophilized research peptide in 10 mg vials, 99%+ HPLC purity, third-party tested, made and shipped in Canada.
Lab-tested research doses · flat $30 CAD Xpresspost · CoA on the product page
Section 01 — Definition
BPC-157 — Body Protection Compound-157 — is a synthetic 15-amino-acid peptide, a stable fragment derived from a protective protein found in human gastric juice. It is one of the most-studied peptides in preclinical tissue-repair research.
In animal and in-vitro models, BPC-157 is investigated for cytoprotective and regenerative activity across several tissue systems — tendon and ligament, muscle, the gut lining, and the vascular network. The interest centres on how a single small peptide appears active across so many injury models at once.
Helix North supplies BPC-157 strictly as a lyophilized research material for in-vitro and laboratory use. Everything on this page is written for research handling and sourcing — it is not dosing guidance and not for human use.
A stable fragment of a gastric protective protein — BPC-157 is the body-protection compound at the centre of peptide tissue-repair research.
Section 02 — Research
What makes BPC-157 unusual is its breadth. Most research peptides are studied in one system; BPC-157 appears in preclinical literature across several at once, which is why it is described as a “body-protective” compound rather than a single-target one.
| Research area | Model focus |
|---|---|
| Tendon & ligament | Connective-tissue repair |
| Gut / GI lining | Mucosal protection |
| Muscle | Recovery models |
| Vascular | Angiogenesis (VEGFR2) |
A recurring thread across these models is angiogenesis — the formation of new blood vessels — alongside modulation of growth-factor and nitric-oxide signalling. This is preclinical, mechanism-level research; none of it constitutes evidence of a human therapeutic effect.
For the full picture, our what is BPC-157 explainer goes deeper, and the BPC-157 + TB-500 (Wolverine stack) article covers how it is studied alongside TB-500 for connective-tissue research.
The same literature is also the only real source on tolerability. Because BPC-157 has never completed a controlled human trial, there is no established safety profile — what exists is animal-model data and a large volume of unverified anecdote, which are routinely conflated. Our review of the reported BPC-157 side effects separates the two and is explicit about where the evidence runs out.
Section 03 — Product
BPC-157 is stocked as a 10 mg lyophilized vial, and as pre-blended BPC-157 + TB-500 research vials — the “Wolverine” blend — for connective-tissue work. Each vial ships freeze-dried for research handling; CoAs are linked where available.
Every lot is sent to an independent third-party laboratory for HPLC purity analysis, with identity confirmed by mass spectrometry. We do not release a lot below 99 percent purity, Where a CoA is held, its lot number, chromatogram, and calculated purity are published on the relevant product page before ordering.
BPC-157 also circulates in oral capsule form, and the two formats are not interchangeable in research terms — they differ in how the peptide survives the digestive tract and therefore in what a study can actually measure. Our oral vs injectable BPC-157 comparison covers the stability and bioavailability arguments behind that split.
Choose a form below, or read how each lot is tested on our lab testing and CoA page.
Section 04 — Handling
BPC-157 ships freeze-dried and is reconstituted with bacteriostatic water before use. The diluent volume is the only real decision, because it sets the concentration of the finished research stock — concentration is simply mass divided by volume.
Wipe both stoppers with an alcohol prep pad, draw the chosen volume of bacteriostatic water into an insulin syringe, and add it slowly down the inside wall of the vial. Swirl gently until clear — never shake — then refrigerate at 2 to 8°C. A 10 mg vial reconstituted with 2 mL gives a 5 mg/mL stock; the same vial with 5 mL gives 2 mg/mL.
Our step-by-step BPC-157 reconstitution guide works the concentration math, and the storage guide covers stability. Once a stock concentration is set, the BPC-157 dosage chart converts it into U-100 syringe units, and the peptide reconstitution calculator handles any combination directly. These are reconstitution mechanics for laboratory handling only — not dosing recommendations.
Section 05 — Sourcing
Sourcing BPC-157 domestically removes the two problems that come with an offshore order: the customs wait and the currency markup. A Canadian-domestic shipment never crosses a border, so there is no customs hold and no risk of a package being detained or returned mid-protocol.
Helix North makes its peptides in Canada and ships BPC-157 anywhere in Canada by Canada Post Xpresspost — typically 2 to 4 business days to Ontario and Quebec, 2 to 3 to the Prairies, 1 to 2 in British Columbia, a flat $30 to any postal code, tracked and in plain packaging. Pricing is in Canadian dollars, so the number on the product page is the number on the receipt.
BPC-157 is legal to purchase and possess for research in Canada and is not a controlled substance. It is supplied strictly as a research material. New here? The Canadian research peptides overview covers testing and shipping, and our BPC-157 + TB-500 (Wolverine stack) article covers the blend most researchers pair it with.
Section 06 — Common questions
Choose a 10 mg vial or a BPC/TB “Wolverine” blend with a third-party CoA, or browse the full research line. Questions about lots or bulk quantities — get in touch.